Juliana has post-doctorate from the University of São Paulo (ICB / USP), degree in Biological Sciences from Federal University of Alfenas (2002-2006), master's (2007/2009) and doctorate (2009/2012) in Sciences from Coordination of Diseases Control, Department of State Health (CCD / SP), Adolfo Lutz Institute - SP, with sandwich period at London School of Hygiene Tropical Medicine - University of London. She is currently Professor of Parasitology at Faculty of Medicine of Jundiaí. She has experience in the area of Parasitology, in the research of new drugs for Leishmaniasis. She operates on the following topics: Research and investigation of the antiparasitic mechanism of action of drugs, combination therapies, selective targeting using liposomes and evaluation of synthetic and natural products against Leishmania sp., Trypanosoma cruzi and Toxoplasma gondii. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Toxoplasma gondii infects animals and humans, with about 30% of world population carrying the parasite, mostly in its latent form. T. gondii is a common cause of serious congenital infections, resulting in both severe fetal disease and subsequent illnesses in children and adults. Toxoplasmosis also causes serious illnesses in immunocompromised individuals, including encephalitis, choriore…
Toxoplasma gondii infects animals and humans, with about 30% of world population carrying the parasite, mostly in its latent form. T. gondii is a common cause of serious congenital infections, resulting in both severe fetal disease and subsequent illnesses in children and adults. Toxoplasmosis also causes serious illnesses in immunocompromised individuals, including encephalitis, choriore…
Toxoplasmosis, caused by the protozoan Toxoplasma gondii, poses a global threat, affecting approximately one-third of the world's population. While often asymptomatic, the infection can be fatal, particularly in immunocompromised individuals, leading to toxoplasmic encephalitis. The current treatment, based on pyrimethamine and sulfadiazine, exhibits limited efficacy and issues related to…
Leishmaniasis is endemic in 98 countries, with about 12 million people infected worldwide. Visceral leishmaniasis (VL), given its high incidence and mortality, is considered by the World Health Organization as one of the most important diseases nowadays. Leishmaniasis treatment relies on a limited therapeutic arsenal, with toxic drugs administered by the parenteral route such as pentavale…
Leishmaniasis is a disease caused by Leishmania parasites, found in 88 countries and with 12 million infected people. Despite the incidence and high lethality, Visceral Leishmaniasis (VL) is considered by the World Health Organization one of the most important diseases. The treatment makes use of drugs with high toxicity as the pentavalent antimonials, amphotericin B and pentamidine, demo…
Protozoan parasitic diseases affect the poorest populations in the world, and consequently are not seen as potential markets. Visceral Leishmaniasis is characterized by a fatal and progressive disease, which is endemic in 88 countries, and according to WHO, it is among the six more important endemic diseases. The treatment employs toxic drugs as pentavalent antimonials, anfotericin B and …
| 2 / 2 | Ongoing research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 3 / 3 | Completed scholarships in Brazil |
| 6 / 6 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID